查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1771583

美国Ultomiris 製药市场规模、份额、趋势分析报告：按适应症、最终用途、分销管道、细分市场预测，2025-2033 年

U.S. Ultomiris Drug Market Size, Share & Trends Analysis Report By Indication (Paroxysmal Nocturnal Hemoglobinuria, Atypical Hemolytic Uremic Syndrome ), By End Use, By Distribution Channel, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

美国Ultomiris医药市场的规模与趋势：

预计 2024 年美国Ultomiris Pharmaceuticals 市场规模为 14.6 亿美元，到 2033 年将达到 81.4 亿美元，2025 年至 2033 年的复合年增长率为 19.93%。

Ultomiris 因其延长的给药间隔提高了患者的依从性和便利性，持续获得认可，成为医疗保健提供者的首选。此外，重症肌无力 (gMG) 和视神经脊髓炎频谱障碍 (NMOSD) 等临床适应症的不断增加也促进了市场的成长。

阵发性肾丝球肾炎 (PNH)、非典型溶血性尿毒症症候群 (aHUS) 和重症肌无力 (gMG) 等罕见自体免疫疾病和血液疾病的盛行率上升也在推动市场成长。例如，FDA 于 2022 年 4 月核准Ultomiris 用于治疗抗乙酰胆碱受体抗体阳性的 gMG 成年患者，扩大了 Ultomiris 的治疗范围并加强了其在神经病学领域的地位。此外，FDA 于 2024 年 3 月对 Ultomiris 用于治疗视神经脊髓炎频谱障碍 (NMOSD) 的优先审查支持了该公司强大的产品线。Astra Zeneca和 Alexion 的策略行销，加上美国先进的医疗基础设施和高诊断率，支持了市场的持续扩张。 Ultomiris 是一种每八週静脉注射一次的长效 C5补体抑制剂，是治疗补体介导疾病的合适药物。

Ultomiris (ravulizumab-cwvz) 由 Alexion Pharmaceuticals 开发，并于 2021 年被Astra Zeneca收购，正在对美国罕见疾病市场产生巨大影响。 2024 年上半年，Ultomiris 在美国的销售额为 10.32 亿美元，较去年同期成长 27%。这一增长得益于适应症的扩大以及与其前身Soliris 的转变。

在美国血液学市场，Ultomiris（ravulizumab）、Hemlibra（emicizumab）和Vafseo（vadadustat）在2023年贡献了45%的销售额成长。光是Ultomiris就贡献了21%的成长，这得益于适应症扩大和核准的批准。

Astra Zeneca将ULTOMIRIS策略性扩展至视神经脊髓炎频谱障碍 (NMOSD)，彰显了其致力于拓展此药物治疗用途的承诺。 2024年3月，美国FDA核准Ultomiris用于治疗视神经脊髓炎频谱障碍 (NMOSD)，使其成为首个也是唯一一个用于此适应症的长效C5补体抑制剂。此次核准基于CHAMPION-NMOSD试验，该试验表明，接受ULTOMIRIS治疗的患者在中位73週的治疗期内未復发。

目录

第一章调查方法与范围

第二章执行摘要

第三章美国Ultomiris 药物市场变数、趋势与范围

  • 市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 商业环境分析
    • 产业分析-波特五力分析
    • PESTLE分析
    • 管道分析
    • 专利到期分析
    • 定价分析

第四章美国Ultomiris药品市场：适应症业务分析

  • 2024年及2033年指示市场占有率
  • 指示细分仪表板
  • 2021 年至 2033 年市场规模、预测与趋势分析（按适应症）
  • 阵发性睡眠性血尿症（PNH）
  • 非典型溶血性尿毒症症候群（aHUS）
  • 全身性重症肌无力（gMG）
  • 视神经脊髓炎频谱障碍 (NMOSD)

第五章美国Ultomiris 製药市场：最终用途业务分析

  • 2024年及2033年最终用途市场占有率
  • 最终用途细分仪表板
  • 按最终用途分類的市场规模、预测和趋势分析（2021-2033 年）
  • 成人
  • 孩子们

第六章美国Ultomiris Pharmaceuticals市场：分销通路业务分析

  • 2024年及2033年分销通路市场占有率
  • 分销通路细分仪表板
  • 按分销管道分類的市场规模、预测和趋势分析（2021-2033 年）
  • 医院药房
  • 零售药局
  • 网路药局

第七章 竞争态势

  • 参与者概览
  • 企业市场分析
  • 公司分类
  • 战略地图
  • 公司简介/上市公司
    • Alexion Pharmaceuticals（AstraZeneca）
Product Code: GVR-4-68040-622-5

U.S. Ultomiris Drug Market Size & Trends:

The U.S. ultomiris drug market size was estimated at USD 1.46 billion in 2024 and is projected to reach USD 8.14 billion by 2033, growing at a CAGR of 19.93% from 2025 to 2033. Ultomiris continues to gain traction due to its extended dosing interval, which improves patient compliance and convenience, making it a preferred choice among healthcare providers. In addition, its expanding clinical indications, including generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD), are contributing to market growth.

The rising prevalence of rare autoimmune and hematologic conditions, such as PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis (gMG), fuels market growth. For instance, the FDA's approval of Ultomiris for adults with anti-AChR antibody-positive gMG in April 2022 has expanded its therapeutic reach, strengthening its position in the neurology segment. In addition, the FDA's priority review in March 2024 for Ultomiris in neuromyelitis optica spectrum disorder (NMOSD) underscores its robust pipeline. Strategic marketing by AstraZeneca and Alexion, coupled with advanced medical infrastructure and high diagnosis rates in the U.S., supports sustained market expansion. The drug's role as a long-acting C5 complement inhibitor, administered intravenously every 8 weeks, positions it as a preferred choice for managing complement-mediated disorders.

Ultomiris (ravulizumab-cwvz), developed by Alexion Pharmaceuticals and acquired by AstraZeneca in 2021, has significantly impacted the U.S. rare disease market. In the first half of 2024, Ultomiris generated USD 1.032 billion in U.S. sales, marking a 27% increase over the previous year. This growth is attributed to expanding indications and a shift from its predecessor, Soliris.

In the U.S. hematological disorders market, Ultomiris (ravulizumab), Hemlibra (emicizumab), and Vafseo (vadadustat) collectively contributed 45% of the market's sales growth in 2023. Ultomiris alone accounted for 21% of this growth, driven by its expanded indications and regulatory approvals.

AstraZeneca's strategic expansion of Ultomiris into neuromyelitis optica spectrum disorder (NMOSD) underscores its commitment to broadening the drug's therapeutic applications. In March 2024, the U.S. FDA approved Ultomiris for NMOSD, making it the first and only long-acting C5 complement inhibitor for this indication. The approval was based on the CHAMPION-NMOSD trial, which demonstrated zero relapses among patients treated with Ultomiris over a median duration of 73 weeks.

U.S. Ultomiris Drug Market Report Segmentation

This report forecasts revenue growth in the U.S. and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. Ultomiris drug market report based on indication, end use, distribution channel, and region:

  • Indication Outlook (Revenue, USD Million, 2021 - 2033)
  • Paroxysmal Nocturnal Hemoglobinuria (PNH)
  • Atypical Hemolytic Uremic Syndrome (aHUS)
  • Generalized Myasthenia Gravis (gMG)
  • Neuromyelitis Optica Spectrum Disorder (NMOSD)
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Adult
  • Pediatric
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Indication
    • 1.2.2. End Use
    • 1.2.3. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Ultomiris Drug Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. U.S. Ultomiris Drug Market: Indication Business Analysis

  • 4.1. Indication Market Share, 2024 & 2033
  • 4.2. Indication Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Million)
  • 4.4. Paroxysmal Nocturnal Hemoglobinuria (PNH)
    • 4.4.1. Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, 2021 - 2033 (USD Million)
  • 4.5. Atypical Hemolytic Uremic Syndrome (aHUS)
    • 4.5.1. Atypical Hemolytic Uremic Syndrome (aHUS) Market, 2021 - 2033 (USD Million)
  • 4.6. Generalized Myasthenia Gravis (gMG)
    • 4.6.1. Generalized Myasthenia Gravis (gMG) Market, 2021 - 2033 (USD Million)
  • 4.7. Neuromyelitis Optica Spectrum Disorder (NMOSD)
    • 4.7.1. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market, 2021 - 2033 (USD Million)

Chapter 5. U.S. Ultomiris Drug Market: End Use Business Analysis

  • 5.1. End Use Market Share, 2024 & 2033
  • 5.2. End Use Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by End Use, 2021 to 2033 (USD Million)
  • 5.4. Adult
    • 5.4.1. Adult Market, 2021 - 2033 (USD Million)
  • 5.5. Pediatric
    • 5.5.1. Pediatric Market, 2021 - 2033 (USD Million)

Chapter 6. U.S. Ultomiris Drug Market: Distribution Channel Business Analysis

  • 6.1. Distribution Channel Market Share, 2024 & 2033
  • 6.2. Distribution Channel Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
  • 6.4. Hospital Pharmacies
    • 6.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
  • 6.5. Retail Pharmacies
    • 6.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
  • 6.6. Online Pharmacies
    • 6.6.1. Online Pharmacies Market, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Alexion Pharmaceuticals (AstraZeneca)
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 U.S. Ultomiris Drug market, by indication, 2021 - 2033 (USD Million)
  • Table 4 U.S. Ultomiris Drug market, by end use, 2021 - 2033 (USD Million)
  • Table 5 U.S. Ultomiris Drug market, by distribution channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Ultomiris Drug market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and application outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Ultomiris Drug market dynamics
  • Fig. 12 Ultomiris Drug market: Porter's five forces analysis
  • Fig. 13 Ultomiris Drug market: PESTLE analysis
  • Fig. 14 Indication market, 2021 - 2033 (USD Million)
  • Fig. 15 Paroxysmal Nocturnal Hemoglobinuria (PNH) market, 2021 - 2033 (USD Million)
  • Fig. 16 Atypical Hemolytic Uremic Syndrome (aHUS) market, 2021 - 2033 (USD Million)
  • Fig. 17 Generalized Myasthenia Gravis (gMG) market, 2021 - 2033 (USD Million)
  • Fig. 18 Neuromyelitis Optica Spectrum Disorder (NMOSD) market, 2021 - 2033 (USD Million)
  • Fig. 19 End Use market, 2021 - 2033 (USD Million)
  • Fig. 20 Adult market, 2021 - 2033 (USD Million)
  • Fig. 21 Pediatric market, 2021 - 2033 (USD Million)
  • Fig. 22 Distribution Channel market, 2021 - 2033 (USD Million)
  • Fig. 23 Hospital Pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 24 Retail Pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 25 Online Pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 26 Company market position analysis
  • Fig. 27 Strategic framework